Received the Certificate of Physician Credentials and the EMBA of Zhejiang University.

Mr. Wang founded Winhealth Pharma in 2006. Under his vision and leadership, Winhealth Pharma has been undergoing exponential growth and become a leading rare disease and branded specialty pharmaceutical company, serving patients with rare diseases and unmet medical needs in China and adjacent regions. Mr. Wang built Winhealth into a pharmaceutical company with full blown capabilities spanning all major cycles of the value chain, including portfolio, drug development, clinical research and commercialization.

Prior to founding Winhealth, Mr. Wang served as a Practicing Physician, and then worked at Guotai Junan Securities and Shenzhen Kangzhe Pharmaceutical (HK: 00867). He has extensive experience on general management, leadership and entrepreneurship.

Ms. Hu has extensive experience in financial management and daily operations.

Prior to joining Winhealth, she worked in HangZhi Machinery & Electronics Co., Ltd and Hangzhou Hangdong Lighting Equipment Co., Ltd.

MBA of McGill University

Joining Winhealth in Jan 2019, Mr. Hao brought a wide spectrum of experience and skill sets including strategic innovation, business development, model upgrades, business incubation of rare deseases.

Previously, he served as SVP of strategic development, GM for B2B business at 111 Inc. (NASDAQ: YI), building the nation-wide B2B pharmacy platform from 0 to 1 and participated in the company's IPO in 2018.

Prior to that, he served as the Co-CEO of Sinco Pharm (Hong Kong: 06833), VP and GM of the pharmaceutical business, Finance Director in China for Cardinal Health (NYSE: CAH). He is also a major participant and supported Cardinal Health's USD 470 mln acquisition of Zuellig Pharma in 2010.

He served as the Executive Director of Finance of Eli Lilly in Canada, and the Director of Financial Planning and Procurement for Eli Lilly in China.

Vice President of the Group, General Manager of Basic Business Division

Mr. Xu received his Pharmacy degree from Naval Medical University.

Mr. Xu has extensive experience in marketing management, market intelligence and strategic planning, as well as unique industry analysis capabilities and strategic insights.

Prior to joining Winhealth, Mr. Xu was a National Sales Manager at China NT Pharma Group, and served as the Office Director of Shanghai Shyndec Pharmaceutical Co., Ltd. He was also the Regional Manager of Eli Lilly .

Xiao Li graduated from school of medicine, Wuhan University in 1997 and then worked as a stomatologist in Suzhou Municipal Hospital.

In 2000, she joined pharmaceutical industry. She worked for several multinational companies including Xi’an Janssen, Bristol-Myers Squibb, Sanofi, etc., and served in the diversified positions covering product manager, regional manager, marketing manager, marketing director, and strategic portfolio development director. In the past 21 years, Miss Xiao accumulated rich commercialization experiences and had excellent track records in the pharmaceutical industry through comprehensive products at different life cycle stages in multiple therapeutic areas.

During the period she worked in Sanofi, she successfully accelerated the launch of blockbuster Dupixent, and commercialization progress of several rare disease products such as Fabrazyme and Aldurazyme in China.

MBA in Yale University, Bachelor of economics in Fudan University.

Mr. Jing has 10+ years of investment and capital market experience in healthcare industry in the U.S. and China.

Prior to joining Winhealth, he was the Managing Director for Healthcare Investments at Fosun International New York Office.

Prior to that, he worked at McKinsey (Consultant, Shanghai), Goldman Sachs (Medical Investment Banking Department , New York), and Novartis (CFO office, New Jersey).